Pirfenidone is an antifibrotic agent that has been proven to slow down the progression of idiopathic pulmonary fibrosis (IPF). The aim of this study was to evaluate the efficacy of low-dose pirfenidone (that is, less than 1200 mg/day). We retrospectively reviewed the medical records of patients with IPF. The patients were divided into the following three groups, those who were not treated with pirfenidone (control) and those who were treated with pirfenidone at doses < 1200 mg/day (low-dose group) and ≥ 1200 mg/day (high-dose group). The adjusted mean changes in forced vital capacity (FVC) in 1 year were - 200.7, - 88.4, and - 94.7 mL in the control, low-dose, and high-dose groups (p = 0.021). The FVC declined more significantly in the cont...
Background: Recent trials involving pirfenidone suggest a beneficial effect in the treatment of idio...
Objectives: To analyze the efficacy and adverse events (AEs) of pirfenidone in idiopathic pulmonary...
Background/aim: Phase III trials have demonstrated a significant efficacy and an acceptable safety f...
SummaryBackgroudPrevious pirfenidone trials have only involved patients with mild-to-moderate idiopa...
Aim: The efficacy and safety of pirfenidone have been previously demonstrated in patients with mild-...
Introduction Although pirfenidone slows disease progression in patients with idiopathic pulmonary fi...
Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable lo...
The aim of this study was to determine the effectiveness of pirfenidone in patients with idiopathic ...
SummaryIdiopathic pulmonary fibrosis (IPF) is a debilitating condition with life expectancy of two t...
Rationale: Real-world data on pirfenidone treatment of patients with idiopathic pulmonary fibrosis (...
Rationale: Real-world data on pirfenidone treatment of patients with idiopathic pulmonary fibrosis (...
Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable los...
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable l...
Background In this retrospective Italian study, which involved all major national interstitial lung ...
PubMedID: 30900199Introduction: In this study we aimed to investigate the effectiveness and safety p...
Background: Recent trials involving pirfenidone suggest a beneficial effect in the treatment of idio...
Objectives: To analyze the efficacy and adverse events (AEs) of pirfenidone in idiopathic pulmonary...
Background/aim: Phase III trials have demonstrated a significant efficacy and an acceptable safety f...
SummaryBackgroudPrevious pirfenidone trials have only involved patients with mild-to-moderate idiopa...
Aim: The efficacy and safety of pirfenidone have been previously demonstrated in patients with mild-...
Introduction Although pirfenidone slows disease progression in patients with idiopathic pulmonary fi...
Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable lo...
The aim of this study was to determine the effectiveness of pirfenidone in patients with idiopathic ...
SummaryIdiopathic pulmonary fibrosis (IPF) is a debilitating condition with life expectancy of two t...
Rationale: Real-world data on pirfenidone treatment of patients with idiopathic pulmonary fibrosis (...
Rationale: Real-world data on pirfenidone treatment of patients with idiopathic pulmonary fibrosis (...
Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable los...
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable l...
Background In this retrospective Italian study, which involved all major national interstitial lung ...
PubMedID: 30900199Introduction: In this study we aimed to investigate the effectiveness and safety p...
Background: Recent trials involving pirfenidone suggest a beneficial effect in the treatment of idio...
Objectives: To analyze the efficacy and adverse events (AEs) of pirfenidone in idiopathic pulmonary...
Background/aim: Phase III trials have demonstrated a significant efficacy and an acceptable safety f...